Related Experiment Video
Updated: Apr 1, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
18.1K
Edoxaban.
Dennis J Cada1, Danial E Baker2, Kyle Ingram3
1Founder and Contributing Editor, The Formulary , Washington State University Spokane , Spokane, Washington.
Hospital Pharmacy
|October 9, 2015
Summary
The Formulary Monograph Service provides monthly drug monographs and utilization evaluations for Pharmacy & Therapeutics Committees. This service aids in informed drug selection and management for healthcare facilities.
Area of Science:
- Pharmacology
- Drug Information Services
- Healthcare Management
Background:
- The Formulary Monograph Service delivers essential drug information to healthcare professionals.
- It targets Pharmacy & Therapeutics Committees, providing timely data on new and investigational drugs.
Purpose of the Study:
- To offer comprehensive drug monographs and utilization evaluations.
- To support informed decision-making in formulary management and medication use.
Main Methods:
- Monthly delivery of 5-6 detailed monographs on new or late-phase drugs.
- Inclusion of 1-page summary monographs for pharmacy and nursing in-services.
- Provision of a comprehensive drug utilization evaluation/medication use evaluation (DUE/MUE).
Main Results:
- Subscribers receive print and online access to monographs.
- Customization options are available to meet specific facility needs.
- A monthly drug class review is now included.
Conclusions:
- The service provides a valuable resource for drug management and education.
- It facilitates evidence-based practice for Pharmacy & Therapeutics Committees.
- The July 2015 topics included ivabradine, dinutuximab, and others, with a focus on ivabradine for safety DUE/MUE.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
01:29Venous Thrombosis III: Interprofessional Care
466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
01:20Antiepileptic Drugs: Potassium Channel Activators
965
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
965
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
15.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.4K